



(51) International Patent Classification:

A61K 39/395 (2006.01) F26B 25/22 (2006.01)
A61K 47/18 (2017.01) A61K 9/19 (2006.01)
A61K 47/26 (2006.01)

(21) International Application Number:

PCT/US2024/026330

(22) International Filing Date:

25 April 2024 (25.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/461,683 25 April 2023 (25.04.2023) US
63/541,455 29 September 2023 (29.09.2023) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: **TANG, Xiaolin**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **BREYDO, Leonid**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agent: **ISACSON, John, P.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS FOR SELECTING EXCIPIENTS AND FOR PREPARING HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS AND OTHER FORMULATIONS COMPRISING PROTEINS




FIG. 1

(57) Abstract: The present inventions relate to methods of preparing highly concentrated monoclonal antibody (mAb) formulations, including screening and selection of excipients to include in mAb formulation. Excipients include amino acids, salts and polyols.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*